Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is ...
(PDF) 1073 AZD5863, a CLDN18.2 and CD3 binding T-cell engager ...
MP0533: A Multispecific Darpin CD3 Engager Targeting CD33, CD123, and ...
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager ...
CD3 - Centre for Drug Design and Discovery | LinkedIn
B7-H6/CD3 T-cell engager | InOncology – Boehringer Ingelheim
Rethinking T Cell Engager Design: CD3–TAA Affinity Co-Optimization Matters
DLL3/CD3 T-cell engager | InOncology – Boehringer Ingelheim
T cell receptor downmodulation induced by bivalent engagement of CD3 or ...
Schematic illustration of Bispecific T-cell Engager (BiTE) structure ...
B7-H6/CD3 T-cell Engager | Clinical Research | InOncology
Nano-bispecific-engager for enhancing T cell function. (A) Design and ...
DLL3/CD3 T-cell Engager | Clinical Research | InOncology
Human endoglin-CD3 bispecific T cell engager antibody induces anti ...
Exogenous TCR engager compliments endogenous antigen presentation for ...
CD3 modulation is required for synergy between anti-CD3 and oral ...
Frontiers | Design of a Trispecific Checkpoint Inhibitor and Natural ...
1068 ATG-107, a novel 2+1 CD3-based T cell engager (TCE) targeting FLT3 ...
AACR 2025: The trispecific T cell engager platform enhances T cell ...
Engineering a tumor selective prodrug T-cell engager bispecific ...
Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks ...
T-cell engager CD3ε | Highlighted Client Publication | genOway
Murine CD3 and fibroblast activation protein‑T‑cell engager‑armed ...
A novel CD3ε fusion receptor allows T cell engager use in TCR-less ...
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML ...
CD3 engagement as a new strategy for allogeneic “off-the-shelf” T cell ...
T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a ...
Engager Clinical Results | InOncology – Boehringer Ingelheim
B7-H6/CD3 T-cell Engager Results | InOncology – Boehringer Ingelheim
Mechanism of action of BiTE technology. BiTE bispecific T cell engager ...
Figure 1 from GBR1302: Effect of CD3-HER2, a bispecific T cell engager ...
ESMO 2024: Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy, in ...
靶向 HER2 或 EGFR 和 CD3 的精确激活的 T 细胞接合剂可减轻实体瘤免疫疗法的靶向、脱瘤毒性,Nature Cancer - X-MOL
Precision-Engineered CD3 T-Cell Engagers for Solid Tumours: Conditional ...
Generalizable design parameters for soluble T cell receptor-based T ...
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in ...
Fine-tuned CD3 Affinity: Desired Balance between Antitumor Activity and ...
(PDF) P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T ...
Full article: Phase I trial of the DLL3/CD3 bispecific T-cell engager ...
(PDF) CD3 engagement as a new strategy for allogeneic “off-the-shelf” T ...
Schematic diagram showing the interaction between CD3 receptors on the ...
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients ...
Assessment of DLL3/CD3 T-cell Engager Obrixtamig for Neuroendocrine ...
Figure 3 from Biodistribution of a CD3/EpCAM bispecific T-cell engager ...
Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive ...
CARs construct design and characterization. (A) Schematic structure of ...
Frontiers | Trispecific eFab-eIg T-cell engagers targeting HER2 and HER3
CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond ...
SITC 2023: Preclinical CD3-based Mouse Models for Evaluation of Bi ...
Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next ...
(PDF) Pre-clinical development of a novel CD3-CD123 bispecific T-cell ...
T-Cell Engagers—The Structure and Functional Principle and Application ...
Innovations in cancer immunotherapy: Bi-specific T cell engagers | CAS
SIM0500 is a humanized GPRC5D-BCMA-CD3 tri-specific antibody ...
Biological activity validation of a computationally designed Rituximab ...
Figure 5 from A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody ...
DAREON-5 (1438-0005) | InOncology – Boehringer Ingelheim
T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions
Design, expression, and purification of hEND-CD3/BiTE. (A) The ...
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell ...
GRAPHIC
【AACR 2025】上细前沿突破四 | TCE核心平台：基于抗CD3与肿瘤特异性靶点的纳米抗体库为精准免疫治疗提供核心工具
全球获批的10款双抗全梳理|CD20|ORR|CD3|双抗|细胞|抗体|靶向|-健康界
TCR Mimic Antibody - Nona Biosciences
Conditionally active T-cell engager. Various approaches to ...
NCT05879978 (1438-0002) | InOncology – Boehringer Ingelheim
DAREON®-7 (1438-0007) | InOncology – Boehringer Ingelheim
DLL3 – A Breakthrough Target for Small Cell Lung Cancer Therapy-DIMA ...
Frontiers | Mechanistic PKPD modeling to describe cytokine release ...
双特异性T细胞衔接器（TCE）-CD3双抗-TCE作用机制/技术平台-德泰生物
BiTE ® antibody constructs target both CD3Ԑ and a tumor-associated ...
NCT05916313 | InOncology – Boehringer Ingelheim
Figure 7 from A First-in-Class Pronectin™-based Bispecific T Cell ...
Emerging Antibodies in Cancer Therapy - Sun - 2023 - Advanced ...
Frontiers | Current landscape and future directions of bispecific ...
A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti ...
Figure 1 from A First-in-Class Pronectin™-based Bispecific T Cell ...
Figure 5 from Mesothelin/CD3 Half-Life–Extended Bispecific T-Cell ...
Bispecific Antibodies Killer Cells at Jamie Stonehouse blog
Full article: Overcoming claudin family homology: discovery of ARC101 ...
(PDF) 1169 AZD5863: a specific, potent, affinity-optimized claudin 18.2 ...
T cell-engager：产生应答的T cells表型详解_生物器材网
Frontiers | Current and future concepts for the generation and ...
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer ...
Extensive‑Stage SCLC Trial (NCT04429087) | InOncology
CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep ...
(PDF) Identification of a high-risk immunogenic prostate cancer patient ...
DAREON®-5 (1438-0005) | InOncology – Boehringer Ingelheim
Expression and purification of the GPC3/CD3 BiTE. (A) Schema of the ...
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG ...
Identification of a high-risk immunogenic prostate cancer patient ...
安进/百济 CD3/STEAP1 双抗国内申报临床_试验_细胞_平台
Antibody Cell Is at Dorothy Maxwell blog
Full Activation of the T Cell Receptor Requires Both Clustering and ...
Figure 4 from A First-in-Class Pronectin™-based Bispecific T Cell ...
